13 – MOLECULAR VARIATIONS BASED ON ISOSTERIC REPLACEMENTS

The replacement in an active molecule of an atom or a group of atoms by another one, presenting a comparable electronic and steric arrangement is based on the concept of isosterism. The development of the concept of isosterism has its roots in the attempts to extend to entire molecules the knowledge acquired for elements, especially the knowledge that two elements possessing an identical peripheral electronic distribution also possess similar chemical properties. The first example in the chapter clearly demonstrates that isosterism does not inevitably imply “isoelectric” structures, but it becomes evident that isoelectronic isosteres show the closest analogies. The main criterion for isosterism is that two isosteric molecules must present similar, if not identical, volumes and shapes. Ideally, isosteric compounds should be isomorphic and able to co-crystallize. Among the other physical properties that isosteric compounds usually share, one can cite boiling point, density, viscosity, and thermal conductivity. However, certain properties must be different: dipolar moments, polarity, polarization, size, and shape. It became evident to the physicists that the concept of isosterism, developed before quantum mechanical theories, could not provide, at the molecular level, the same results as those that the periodic classification had provided for the elements: a correlation between electronic structure, and physical and chemical properties. In the field of medicinal chemistry the isosterism concept, taken in its broadest sense, has proved to be a research tool of the utmost importance. The main reason for this is because isosteres are often much more alike in their biological than in their physical and chemical properties.

[1]  J. Kehne,et al.  3-(2-Carboxyindol-3-yl)propionic acid-based antagonists of the N-methyl-D-aspartic acid receptor associated glycine binding site. , 1992, Journal of medicinal chemistry.

[2]  H. Zilch,et al.  Sila-substitution--a useful strategy for drug design? , 1986, Endeavour.

[3]  G. W. Anderson,et al.  Antihistamine agents; halogenated N,N-dimethyl-N-benzyl-N-(2-pyridyl)-ethylenediamines. , 1949, The Journal of organic chemistry.

[4]  R. C. Young,et al.  Dipole moment in relation to H2 receptor histamine antagonist activity for cimetidine analogues. , 1986, Journal of medicinal chemistry.

[5]  D. Liston,et al.  Syntheses, resolution, and structure-activity relationships of potent acetylcholinesterase inhibitors: 8-carbaphysostigmine analogues. , 1992, Journal of medicinal chemistry.

[6]  E G McMahon,et al.  Nonpeptide angiotensin II antagonists: N-phenyl-1H-pyrrole derivatives are angiotensin II receptor antagonists. , 1993, Journal of medicinal chemistry.

[7]  E. Imamiya,et al.  Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres. , 1996, Journal of medicinal chemistry.

[8]  J. Fauchère Elements for the rational design of peptide drugs , 1986 .

[9]  A. Kozikowski,et al.  Structure-activity relationship studies of cocaine: replacement of the C-2 ester group by vinyl argues against H-bonding and provides an esterase-resistant, high-affinity cocaine analogue. , 1992, Journal of medicinal chemistry.

[10]  M. Parnham,et al.  Seleno-organic compounds and the therapy of hydroperoxide-linked pathological conditions. , 1987, Biochemical pharmacology.

[11]  J. Watkins,et al.  Structure-activity relationships in the development of excitatory amino acid receptor agonists and competitive antagonists. , 1990, Trends in pharmacological sciences.

[12]  H. Grimm Zur Systematik der chemischen Verbindungen vom Standpunkt der Atomforschung, zugleich über einige Aufgaben der Experimentalchemie , 1929, Naturwissenschaften.

[13]  H. Lönnberg,et al.  Synthesis and pharmacological properties of 4(5)-(2-ethyl-2,3-dihydro-2 silainden-2-yl)imidazole, a silicon analogue of atipamezole , 1996 .

[14]  P. Anderson,et al.  N-(1,3,4,6,7,12b-hexahydro-2H-benzo[b]furo[2,3-a]quinolizin -2-yl)-N- methyl-2-hydroxyethane-sulfonamide: a potent and selective alpha 2-adrenoceptor antagonist. , 1985, Journal of medicinal chemistry.

[15]  J. Désiré,et al.  (Aryloxy)methylsilane derivatives as new cholesterol biosynthesis inhibitors: synthesis and hypocholesterolemic activity of a new class of squalene epoxidase inhibitors. , 1995, Journal of medicinal chemistry.

[16]  W. Landauer,et al.  ON THE ROLE OF RIBOFLAVIN IN THE TERATOGENIC ACTIVITY OF BORIC ACID. , 1964, The Journal of experimental zoology.

[17]  Ralph Hirschmann,et al.  Design, synthesis, and crystal structure of a pyrrolinone-based peptidomimetic possessing the conformation of a .beta.-strand: potential application to the design of novel inhibitors of proteolytic enzymes , 1992 .

[18]  I Yanagisawa,et al.  Histamine H2 receptor antagonists. 1. Synthesis of N-cyano and N-carbamoyl amidine derivatives and their biological activities. , 1984, Journal of medicinal chemistry.

[19]  P. Krogsgaard‐Larsen gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. , 1981, Journal of medicinal chemistry.

[20]  J. Drummond,et al.  Convenient procedure for the preparation of alkyl and aryl substituted N-(aminoalkylacyl)sulfonamides , 1988 .

[21]  J. Kardos,et al.  Octahydroindolo[2,3-a]quinolizin-2-one, a novel structure for γ-aminobutyric acid (GABA) uptake inhibition , 1986 .

[22]  R. Hirschmann,et al.  An effective synthesis of scalemic 3,5,5-trisubstituted pyrrolin-4-ones , 1993 .

[23]  C. B. Naylor,et al.  Synthesis and muscarinic activities of quinuclidin-3-yltriazole and -tetrazole derivatives. , 1992, Journal of medicinal chemistry.

[24]  T. Willson,et al.  Synthesis and muscarinic activity of quinuclidinyl- and (1-azanorbornyl)pyrazine derivatives. , 1992, Journal of medicinal chemistry.

[25]  J S Ward,et al.  Novel functional M1 selective muscarinic agonists. Synthesis and structure-activity relationships of 3-(1,2,5-thiadiazolyl)-1,2,5,6-tetrahydro-1-methylpyridines . , 1992, Journal of medicinal chemistry.

[26]  Aalt Bast,et al.  Comprehensive medicinal chemistry , 1991 .

[27]  B. T. Phillips,et al.  Inhibitors of gastric acid secretion: 3,4-diamino-1,2,5-thiadiazole 1-oxides and 1,1-dioxides as urea equivalents in a series of histamine H2-receptor antagonists. , 1982, Journal of medicinal chemistry.

[28]  R. D. Dyer,et al.  Hydroxamic acid inhibitors of 5-lipoxygenase. , 1987, Journal of medicinal chemistry.

[29]  H. Erlenmeyer,et al.  Zusammenhänge zwischen Konstitution und Wirkung bei Pyrazolonderivaten , 1935 .

[30]  T. Honoré,et al.  Muscarinic cholinergic agonists and antagonists of the 3-(3-alkyl-1,2,4-oxadiazol-5-yl)-1,2,5,6-tetrahydropyridine type. Synthesis and structure-activity relationships. , 1991, Journal of medicinal chemistry.

[31]  E. Browning Toxicity of Industrial Metals , 1961 .

[32]  P. Contreras,et al.  Preparation and opioid activity of analogues of the analgesic dipeptide 2,6-dimethyl-L-tyrosyl-N-(3-phenylpropyl)-D-alaninamide. , 1992, Journal of medicinal chemistry.

[33]  M. Drysdale,et al.  Rationally designed "dipeptoid" analogues of CCK. Acid mimics of the potent and selective non-peptide CCK-B receptor antagonist CI-988. , 1992, Journal of medicinal chemistry.

[34]  R. Barth,et al.  Boron compounds for neutron capture therapy. , 1989, Basic life sciences.

[35]  J. Kraus Isosterism and molecular modification in drug design: new n-dipropylacetate analogs as inhibitors of succinic semi aldehyde dehydrogenase. , 1983, Pharmacological research communications.

[36]  A. Sleight,et al.  Novel agonists of 5HT2C receptors. Synthesis and biological evaluation of substituted 2-(indol-1-yl)-1-methylethylamines and 2-(indeno[1,2-b]pyrrol-1-yl)-1-methylethylamines. Improved therapeutics for obsessive compulsive disorder. , 1997, Journal of medicinal chemistry.

[37]  L L Iversen,et al.  Novel quinuclidine-based ligands for the muscarinic cholinergic receptor. , 1990, Journal of medicinal chemistry.

[38]  R. McGuire,et al.  Principal components describing biological activities and molecular diversity of heterocyclic aromatic ring fragments. , 1996, Journal of medicinal chemistry.

[39]  F. Lichtenthaler,et al.  Intermediates in the Formation of γ‐Pyrones from Hexose Derivatives: A Simple Synthesis of Kojic Acid and Hydroxymaltol , 1969 .

[40]  C. Lipinski,et al.  Hydantoin bioisosteres. In vivo active spiro hydroxy acetic acid aldose reductase inhibitors. , 1992, Journal of medicinal chemistry.

[41]  T. Goodson,et al.  Leukotriene receptor antagonists. 1. Synthesis and structure-activity relationships of alkoxyacetophenone derivatives. , 1987, Journal of medicinal chemistry.

[42]  Luis Carrasco,et al.  Synthesis and antiviral evaluation of nucleosides of 5-methylimidazole-4-carboxamide. , 1985, Journal of Medicinal Chemistry.

[43]  T. Burke,et al.  Inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands. 2. 4-(2-Malonyl)phenylalanine as a potent phosphotyrosyl mimetic. , 2000, Journal of medicinal chemistry.

[44]  J. Kraus,et al.  Isosterism and molecular modification in drug design: tetrazole analogue of GABA: effects on enzymes of the gamma-aminobutyrate system. , 1983, Pharmacological research communications.

[45]  W. Landauer,et al.  On the chemical production of developmental abnormalities and of phenocopies in chicken embryos. , 1954, Journal of cellular physiology. Supplement.

[46]  H. Fischer,et al.  A novel biologically active selenoorganic compound. VIII. Biotransformation of ebselen. , 1988, Xenobiotica; the fate of foreign compounds in biological systems.

[47]  P. Krogsgaard‐Larsen,et al.  Recent Advances in GABA Agonists, Antagonists and Uptake Inhibitors: Structure–Activity Relationships and Therapeutic Potential , 1988 .

[48]  B. Matthews,et al.  Thiorphan and retro-thiorphan display equivalent interactions when bound to crystalline thermolysin. , 1989, Biochemistry.

[49]  R. Chang,et al.  Nonpeptide angiotensin II antagonists derived from 4H-1,2,4-triazoles and 3H-imidazo[1,2-b][1,2,4]triazoles. , 1993, Journal of medicinal chemistry.

[50]  C G Wermuth,et al.  Aminopyridazines--an alternative route to potent muscarinic agonists with no cholinergic syndrome. , 1993, Farmaco.

[51]  J. Dunitz,et al.  Structure of boromycin. , 1971, Helvetica chimica acta.

[52]  B. Roques,et al.  Synthesis of new amino acids mimicking sulfated and phosphorylated tyrosine residues , 1988 .

[53]  E. Grant,et al.  The dipole moments of 1,3-dimethylthiourea, 1,3-dimethyl-2-cyanoguanidine and 1,1-bis-methylamino-2-nitroethene in a aqueous solution , 1982 .

[54]  C. Wermuth,et al.  Analogues tétrazoliques d'agents GABA-mimétiques , 1984 .

[55]  J. Hawkinson,et al.  Subtype-selective N-methyl-D-aspartate receptor antagonists: synthesis and biological evaluation of 1-(arylalkynyl)-4-benzylpiperidines. , 1999, Journal of medicinal chemistry.

[56]  G Bolliger,et al.  Muscarinic activity of the thiolactone, lactam, lactol, and thiolactol analogues of pilocarpine and a hypothetical model for the binding of agonists to the m1 receptor. , 1992, Journal of medicinal chemistry.

[57]  R. Passmore,et al.  BIOCHEMICAL LESIONS AND LETHAL SYNTHESIS , 1964 .

[58]  R. Winneker,et al.  Antiandrogenic steroidal sulfonyl heterocycles. Utility of electrostatic complementarity in defining bioisosteric sulfonyl heterocycles. , 1992, Journal of medicinal chemistry.

[59]  D. Binder,et al.  Thiophen als Strukturelement physiologisch aktiver Substanzen, 16. Mitt. Thienoisoxazole durch Substitution am Oximstickstoff , 1987 .

[60]  M. Reich,et al.  Potential antiatherosclerotic agents. 3. Substituted benzoic and non benzoic acid analogues of cetaben. , 1983, Journal of medicinal chemistry.

[61]  H. Nagasawa,et al.  Acyl, N-protected alpha-aminoacyl, and peptidyl derivatives as prodrug forms of the alcohol deterrent agent cyanamide. , 1986, Journal of medicinal chemistry.

[62]  D. Junquéro,et al.  Design and synthesis of new hypocholesterolemic organosilanes with antioxidant properties , 1996 .

[63]  J. Büchi,et al.  Über lokalanästhetisch wirksame basische Ester und Amide verschiedener Alkoxy-amino-benzoesäuren , 1951 .

[64]  A. Jeng,et al.  Potent non-peptidic dual inhibitors of endothelin-converting enzyme and neutral endopeptidase 24.11 , 1997 .

[65]  W. S. Sheldrick,et al.  Sila-Pharmaka, XIX. Sila-Pridinol und Pridinol: Darstellung und Eigenschaften sowie Strukturen im kristallinen und gelösten Zustand , 1980 .

[66]  Gabriele Cruciani,et al.  A New Set of Principal Properties for Heteroaromatics Obtained by GRID , 1996 .

[67]  E. Grant,et al.  The dielectric properties of seven polar amidine-containing compounds of biological interest , 1985 .

[68]  J. Katzenellenbogen,et al.  Acylamino boronic acids and difluoroborane analogues of amino acids: potent inhibitors of chymotrypsin and elastase. , 1985, Journal of medicinal chemistry.

[69]  Thierry Langer,et al.  New Principal Components Derived Parameters Describing Molecular Diversity of Heteroaromatic Residues , 1998 .

[70]  Fessenden Rj,et al.  The biological properties of silicon compounds. , 1967 .

[71]  K. H. Lee,et al.  Comparison of analgesic effects of isosteric variations of salicylic acid and aspirin (acetylsalicylic acid) , 1975 .

[72]  L. H. Sommer,et al.  STEREOCHEMISTRY OF HYDRIDE ION DISPLACEMENT FROM SILICON. ENHANCED RATES AT BRIDGEHEAD AND 4-RING SILICON ATOMS1 , 1957 .

[73]  A. S. Chawla,et al.  Medicinal chemistry of tetrazoles. , 1980, Progress in medicinal chemistry.

[74]  A. Larsen,et al.  A New Bio-isostere : Alkylsulphonamidophenethanolamines , 1964, Nature.

[75]  Christopher M Thomas,et al.  Synthesis and evaluation of 2-pyridinone derivatives as HIV-1-specific reverse transcriptase inhibitors. 2. Analogues of 3-aminopyridin-2(1H)-one. , 1992, Journal of medicinal chemistry.

[76]  Y. Pommier,et al.  The novel silatecan 7-tert-butyldimethylsilyl-10-hydroxycamptothecin displays high lipophilicity, improved human blood stability, and potent anticancer activity. , 2000, Journal of medicinal chemistry.

[77]  J. Deeter,et al.  Indazoles as indole bioisosteres: synthesis and evaluation of the tropanyl ester and amide of indazole-3-carboxylate as antagonists at the serotonin 5HT3 receptor. , 1987, Journal of medicinal chemistry.

[78]  W. Kinney,et al.  Bioisosteric replacement of the alpha-amino carboxylic acid functionality in 2-amino-5-phosphonopentanoic acid yields unique 3,4-diamino-3-cyclobutene-1,2-dione containing NMDA antagonists. , 1992, Journal of medicinal chemistry.

[79]  W. Günther,et al.  Organic selenium compounds: their chemistry and biology. , 1973 .

[80]  D. Anderson,et al.  Ligands for brain cholinergic channel receptors: synthesis and in vitro characterization of novel isoxazoles and isothiazoles as bioisosteric replacements for the pyridine ring in nicotine. , 1994, Journal of medicinal chemistry.

[81]  Y. Masuda,et al.  Studies on 3-substituted 1,2-benzisoxazole derivatives. 6. Syntheses of 3-(sulfamoylmethyl)-1,2-benzisoxazole derivatives and their anticonvulsant activities. , 1979, Journal of medicinal chemistry.

[82]  R. Bergeron,et al.  Structural alterations in desferrioxamine compatible with iron clearance in animals. , 1992, Journal of Medicinal Chemistry.

[83]  Paul A. Bartlett,et al.  Differential binding energy: a detailed evaluation of the influence of hydrogen-bonding and hydrophobic groups on the inhibition of thermolysin by phosphorus-containing inhibitors , 1991 .

[84]  R. Franke,et al.  Discriminant--analytical investigation on the structural dependence of hyperglycemic and hypoglycemic activity in a series of substituted o-toluenesulfonylthioureas and o-toluenesulfonylureas. , 1979, Journal of medicinal chemistry.

[85]  D. R. Curtis,et al.  Novel class of amino acid antagonists at non-N-methyl-D-aspartic acid excitatory amino acid receptors. Synthesis, in vitro and in vivo pharmacology, and neuroprotection. , 1991, Journal of medicinal chemistry.

[86]  H. Köhler,et al.  Dicyanmethanido‐ und Cyanamido‐oxoanionen. Untersuchungen zum sauerstoffanalogen Charakter der C(CN)2‐ und NCN‐Gruppen , 1970 .

[87]  S. Hibi,et al.  Discovery of novel and potent retinoic acid receptor alpha agonists: syntheses and evaluation of benzofuranyl-pyrrole and benzothiophenyl-pyrrole derivatives. , 2000, Journal of medicinal chemistry.

[88]  M. B. Chenoweth,et al.  ON THE MECHANISMS OF THE PHARMACOPHORIC EFFECT OF HALOGENATION. , 1963, Pharmacological reviews.

[89]  P. Wyman,et al.  7-Aroyl-2,3-dihydrobenzo[b]furan-3-carboxylic acids and 7-benzoyl-2,3-dihydrobenzo[b]thiophene-3-carboxylic acids as analgesic agents. , 1986, Journal of medicinal chemistry.

[90]  I. Langmuir ISOMORPHISM, ISOSTERISM AND COVALENCE. , 1919 .

[91]  A. Jeng,et al.  Design and synthesis of potent, selective inhibitors of endothelin-converting enzyme. , 1998, Journal of medicinal chemistry.

[92]  P. Goldman The carbon-fluorine bond in compounds of biological interest. , 1969, Science.

[93]  Christopher A. Lipinski,et al.  Chapter 27. Bioisosterism in Drug Design , 1986 .

[94]  J. Rokach,et al.  Kojic amine--a novel gamma-aminobutyric acid analogue. , 1979, Journal of medicinal chemistry.

[95]  B. Lipworth Leukotriene-receptor antagonists , 1999, The Lancet.

[96]  C. Thornber,et al.  Isosterism and molecular modification in drug design , 1979 .

[97]  T. Burke,et al.  Preparation of fluoro- and hydroxy-4-(phosphonomethyl)-D,L-phenylalanine suitably protected for solid-phase synthesis of peptides containing hydrolytically stable analogs of O-phosphotyrosine , 1993 .

[98]  C. Jennings-White,et al.  Synthesis and biological activity of carboxylic acid replacement analogues of the potent angiotensin converting enzyme inhibitor 5(S)-benzamido-4-oxo-6-phenylhexanoyl-L-proline. , 1985, Journal of medicinal chemistry.